Become a strategic partner for the industrialisation and commercialisation
of this innovation through an operating licence.
SUCCESS
Development of a ‘Live Biotherapeutics’ for the treatment of IBD
Investment: 555k€
Scope: Health
Scientific field(s): Biology and Medicinal Chemistry
Institution(s): AgroParisTech - INRAE - Inserm - AP-HP - Sorbonne Université
Development: Technology to be marketed
#1
Live biotherapy targeting a major unmet medical need
#2
A unique strain derived from healthy microbiota, with proven efficacy
#3
A mature project, adaptable as a probiotic or medicine
USE CASES
- Approximately 8 millions patients suffer from inflammatory bowel disease (IBD).
- 70% of patients with IBD require second-line treatments in the long term, and 20-30% are refractory to various treatments.
- Protective effect on intestinal inflammation in a colitis model
APPLICATIONS
An LBP product (Live Biotherapeutics), using an isolated strain (C.Comes) from the gut flora of a healthy person, presenting the capacity to restore a key function of the microbiota that is altered by IBD.
ADVANTAGES
- Addressing an unmet medical need
- Alternative or supplement to current treatments
- It could be developed as a probiotic or as a drug
- Expert scientific and clinical team